Indeed, CAPS enhances the cytotoxicity of chemotherapeutics or compounds with well-known antitumor action, such as sorafenib and erlotinib, through mechanisms involving AKT inhibition [93,94] in various tumor cells. This evidence concerns the gene AKT1 and neoplasm.